Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing

Contributed by: Business Wire

Logo

Tags

Science

Neurology

Other Science

Biotechnology

Research

Pharmaceutical

Health

Clinical Trials

BIO International Convention 2025

More Like This

Azafaros to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 2025

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders

Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 2025

Azafaros announces positive topline Phase 2 study data with nizubaglustat in GM2 gangliosidosis and Niemann-Pick disease type C

Positive Niemann-Pick disease type C (NPC) and GM2 gangliosidosis data from nizubaglustat Phase 2 RAINBOW study conducted by Azafaros presented at major metabolic disease conference

Axovia Therapeutics Announces Three Upcoming Poster Presentations at ASGCT

PR Newswire associated0

BIAL Announces Oral Presentation at GBA1 Meeting 2025